Resources

PATH has been contributing to Myanmar’s health care transformation since 2012 and supports the government’s commitment to achieve universal health coverage by 2030. PATH works with the government, nongovernmental actors, and the private sector to leverage partnerships, policy advocacy, new technologies, and innovative approaches to address inequities in key health areas—nutrition, vaccines and immunization, sexual and reproductive health, infectious diseases, and noncommunicable diseases.

This national strategy is to be used to guide elimination of human African trypanosomiasis in the Democratic Republic of the Congo.

This document describes the methods and procedures that were determined to provide the optimal results. The methods and procedures described in this document have been utilized by PATH and other researchers with favorable results that correlate well with ELISA results and/or microfilaria staus. The goal of this document is to broadly disseminate these methods and procedures as best practices for utilizing DBS specimens with the rapid tests to the onchocerciasis community.

The new, four-year Devices, Diagnostics, and Drugs to Address Women’s Needs Product Development Partnership (D3AWN PDP) is tapping into PATH’s deep PDP expertise to develop and introduce a portfolio of devices, diagnostics, and drugs to prevent or manage preeclampsia/eclampsia (PE/E) and PPH. The D3AWN PDP is advancing affordable, accessible, safe, and effective tools for sub-Saharan communities. Solutions include:Heat-stable FDT for PPH prevention: Sublingual oxytocin in heat-stable, fast dissolving tablet.Reusable, electricity-free infusion pump for the delivery of lifesaving nutrients, fluids, and medicines: RELI Delivery System.Uterine balloon tamponade for the management of PPH: Sinapi Ellavi Uterine Balloon Tamponade.Urinary dipstick test with protein to creatinine ratiometric measurement for improved preeclampsia screening

L’évaluation prospective de pays (PCE) est une plateforme d’évaluation intégrée à méthodes mixtes, conçue pour examiner le modèle d’investissement du Fonds mondial, ses investissements et sa contribution aux effets et à l'impact des programmes de lutte contre les épidémies de sida, de tuberculose et de paludisme dans huit pays. La PCE génère des données utiles à l’amélioration des programmes et à l’accélération du progrès vers les objectifs de la stratégie 2017-2022 du Fonds mondial.Cette note présente les conclusions de la RDC ainsi que les résultats synthétisés dans les huit pays PCE en 2018.